TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31560216

Group type: EXPERIMENTAL
Intervention: 1-month dual antiplatelet therapy (DAPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 0
Study: 29233097

Group type: EXPERIMENTAL
Intervention: DE-REACH intervention (12 individual two-weekly sessions, 9 at home, 3 via telephone)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: DE-REACH intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study: 25147363

Group type: EXPERIMENTAL
Intervention: Dominant hand (test 1)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-dominant hand (test 2)
Number of subjects: 41
Study: 23507477

Group type: EXPERIMENTAL
Intervention: HAM-RS2 (48 g dietary fibre from high-amylose maize type 2 resistant starch)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HAM-RS2
Number of subjects: 30
Study: 22114703

Group type: EXPERIMENTAL
Intervention: Regents Academy program for at-risk students during the normal school day and year.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (not specified in detail).
Number of subjects: 0
Study: 19901711

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - Enoxaparin sodium 40mg/d
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control - Long compression stockings (CS)
Number of subjects: 75
Study: 16408299

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 51

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study: 12498603

Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO) treatment started within 2 weeks after birth until soft palate closure at 12 months of age.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-infant orthopedics (non-IO) treatment with extra check-ups at 6 weeks and before and after lip repair and soft palate closure.
Number of subjects: 2
Study: 17170610

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ combination therapy (150 mg/12.5 mg, titrated to 300 mg/25 mg at week 1)
Number of subjects: 737

Group type: COMPARATOR
Intervention: Irbesartan monotherapy (150 mg, titrated to 300 mg at week 1)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ combination therapy
Number of subjects: 737

Group type: COMPARATOR
Intervention: Irbesartan monotherapy
Number of subjects: 737
Study: 10472868

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (10- or 20-mg patch)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Intravenous ritodrine
Number of subjects: 245
Study: 8734594

Group type: EXPERIMENTAL
Intervention: Rosin-coated glass
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glass
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Satin-finished aluminum
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Poly-vinyl chloride (PVC) plastic
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Teflon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nyloprint (polyamide plastic)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subjective estimates of friction
Number of subjects: 10
Study: 1902238

Group type: EXPERIMENTAL
Intervention: Erythromycin (333 mg administered orally every 8 hr for 4 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control treatment (glyburide 5 mg administered on day 4 of each study period)
Number of subjects: 12
Study: 7116714

Group type: EXPERIMENTAL
Intervention: Standardized simulated patient problems
Number of subjects: 37
Study: 31563504

Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair using a transosseous knotless anchor (ATOK)
Number of subjects: 15
Study: 31103114

Group type: EXPERIMENTAL
Intervention: Fascial Manipulation® (FM)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (normal training protocols and standard medical care)
Number of subjects: 29
Study: 28736381

Group type: EXPERIMENTAL
Intervention: Lisinopril treatment (experimental group)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Captopril treatment (control group)
Number of subjects: 210
Study: 25734566

Group type: EXPERIMENTAL
Intervention: Gliadin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Media (control)
Number of subjects: 23
Study: 24827134

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg once daily
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg once daily (after adjustment for baseline characteristics)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg once daily (exploratory analysis)
Number of subjects: 207
Study: 22625844

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention (two face-to-face and four telephonic sessions)
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention
Number of subjects: 928

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 928
Study: 19741011

Group type: COMPARATOR
Intervention: MTX (0.3 mg/kg/week, maximum of 20 mg/week, without escalating dose regimen)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with MTX and ADA (40 mg eow)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: MTX and ADA combination therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 65
Study: 17971594

Group type: EXPERIMENTAL
Intervention: ATA + TOR (Atamestane 500 mg + Toremifene 60 mg)
Number of subjects: 865

Group type: COMPARATOR
Intervention: LET (Letrozole 2.5 mg)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: ATA + TOR
Number of subjects: 865

Group type: COMPARATOR
Intervention: LET
Number of subjects: 865
Study: 15378476

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 3

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 11790868

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily) for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily) for 1 week
Number of subjects: 0
Study: 9508044

Group type: EXPERIMENTAL
Intervention: Pulsed high-frequency electromagnetic fields (900 MHz, pulsed with 217 Hz, average power density 0.02 mW/cm2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulsed high-frequency electromagnetic fields
Number of subjects: 0
Study: 10147334

Group type: EXPERIMENTAL
Intervention: Myopic photorefractive keratectomy excimer laser
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Multizone treatments
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Excimer laser for compound myopic astigmatism
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: General laser technology
Number of subjects: 100000
Study: 27756854

Group type: EXPERIMENTAL
Intervention: PRC‐063 (multilayer-release methylphenidate)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 31026505

Group type: COMPARATOR
Intervention: Silencing of circHIPK3 in ovarian cancer cells (A2780 and SKOV3) and normal ovarian epithelial cells (IOSE80) via siRNA.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CircHIPK3 expression in ovarian cancer tissues.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Analysis of circRNA expression profiling using NGS.
Number of subjects: 36
Study: 28471766

Group type: EXPERIMENTAL
Intervention: Home-based HIV counselling and testing (HCT)
Number of subjects: 121130
Study: 26742307

Group type: EXPERIMENTAL
Intervention: Lixujieyu recipe combined with Gong‐Tune
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lixujieyu recipe combined with Jiao‐Tune
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lixujieyu recipe alone
Number of subjects: 75
Study: 23475691

Group type: EXPERIMENTAL
Intervention: tofacitinib 2 mg twice daily
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice daily
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: tofacitinib 15 mg twice daily
Number of subjects: 197

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: PGA
Number of subjects: 197
Study: 21349585

Group type: EXPERIMENTAL
Intervention: Combined medical and psychological treatment (including antidepressants and health-visitor delivered non-directive counselling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-visitor delivered non-directive counselling
Number of subjects: 0
Study: 18422981

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 52

Group type: COMPARATOR
Intervention: Early loaded implants
Number of subjects: 52
Study: 17063220

Group type: EXPERIMENTAL
Intervention: 40 mg of oral citalopram
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12932601

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison group (no atorvastatin)
Number of subjects: 31
Study: 10834216

Group type: EXPERIMENTAL
Intervention: Chitra bands
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dentaurum bands
Number of subjects: 150
Study: 9403353

Group type: EXPERIMENTAL
Intervention: Flurenizide
Number of subjects: 75

Group type: COMPARATOR
Intervention: Traditional therapy (Control)
Number of subjects: 75
Study: 8403176

Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg.kg‐1 i.v.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3535397

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 25
Study: 31143439

Group type: EXPERIMENTAL
Intervention: Intervention group (treated)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study: 26845191

Group type: EXPERIMENTAL
Intervention: Axitinib (two 5‐mg tablets daily on days 2‐19)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Chemotherapy only (pemetrexed 500 mg/m(2) every 3 weeks and cisplatin 75 mg/m(2) every 3 weeks)
Number of subjects: 25
Study: 24115225

Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers and clinical parameters
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Composite test using TGFβ, HSP-70, at-risk alcohol use, and Child class B
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Blood test for HVPG
Number of subjects: 90
Study: 20231678

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (paclitaxel 225 mg/m(2) and carboplatin AUC 6) followed by surgery
Number of subjects: 354

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 354
Study: 19620483

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 946
Study: 16438075

Group type: EXPERIMENTAL
Intervention: Subcutaneous closure with 2/0 polyglactin sutures (Group-I)
Number of subjects: 152

Group type: COMPARATOR
Intervention: No subcutaneous closure (Group-II)
Number of subjects: 152
Study: 12608907

Group type: EXPERIMENTAL
Intervention: Vector-system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional ultrasonic system
Number of subjects: 20
Study: 10606996

Group type: EXPERIMENTAL
Intervention: Optically guided grasping forceps
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard bronchoscopy forceps
Number of subjects: 80
Study: 8605127

Group type: EXPERIMENTAL
Intervention: Blood folic acid and vitamin B12 levels in neural tube defect pregnancies
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Systematic review of all studies
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 135
Study: 1902154

Group type: EXPERIMENTAL
Intervention: PA catheters with protective sleeves (group 1)
Number of subjects: 102

Group type: COMPARATOR
Intervention: PA catheters without protective sleeves (group 2)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 102
Study: 6820918

Group type: EXPERIMENTAL
Intervention: Tissue Culture Urokinase (TCUK)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Urinary Urokinase (UUK)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: TCUK and UUK (combined with anti-cancer agents)
Number of subjects: 101
Study: 29909433

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (100, 200, or 400 µg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Fentanyl citrate IV 50 µg
Number of subjects: 98
Study: 27304975

Group type: EXPERIMENTAL
Intervention: Bethanechol 150 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bethanechol (all doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Xenin-25
Number of subjects: 30
Study: 25028911

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Ritonavir-boosted Lopinavir (LPV/r)
Number of subjects: 425
Study: 21964975

Group type: EXPERIMENTAL
Intervention: SafeTalk intervention (4-session motivational interviewing-based program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heart-healthy attention-control
Number of subjects: 0
Study: 20032281

Group type: COMPARATOR
Intervention: Chronic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acute exercise
Number of subjects: 0
Study: 20201245

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Memantine + Donepezil
Number of subjects: 43

Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 43
Study: 15925864

Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dynamic posturography on a seesaw platform
Number of subjects: 112

Group type: COMPARATOR
Intervention: Static conditions
Number of subjects: 112

Group type: COMPARATOR
Intervention: Dynamic eyes-closed conditions
Number of subjects: 112

Group type: COMPARATOR
Intervention: Dynamic conditions (pitch and roll planes)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Postural oscillations
Number of subjects: 112
Study: 12622859

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (verum) used twice daily for 3 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo gel used twice daily for 3 weeks
Number of subjects: 50
Study: 10638906

Group type: EXPERIMENTAL
Intervention: SGB with 7 ml of 1% lidocaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1% lidocaine injected intramuscularly (control)
Number of subjects: 10
Study: 8867248

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) at 3 g/kg and higher
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Salicylic acid (SA) at 15 g/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) at 15 g/kg and salicylic acid (SA) at 15 g/kg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Commercial ibuprofen (50 g/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Benzocain creams (100 g/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 6
Study: 1644013

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6373155

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study: 30998528

Group type: EXPERIMENTAL
Intervention: Coffee intake (150 mL, 3 times per day until discharge)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Tea intake (150 mL, 3 times per day until discharge)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Coffee intake
Number of subjects: 115

Group type: COMPARATOR
Intervention: Tea intake
Number of subjects: 115
Study: 28340147

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Needle sensation
Number of subjects: 114
Study: 26728501

Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy (m-CIMT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: control group (conventional therapy)
Number of subjects: 22
Study: 25117849

Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Alcohol craving
Number of subjects: 461
Study: 19386949

Group type: EXPERIMENTAL
Intervention: Integrated Medicines Management (IMM) program
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard pharmaceutical care (Control)
Number of subjects: 117
Study: 17243862

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 6458
Study: 16209958

Group type: EXPERIMENTAL
Intervention: Edifoligide (Corgentech Inc, South San Francisco, Calif)
Number of subjects: 3014

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 3014
Study: 10975216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ANP 0.025 mg x kg(‐1).min(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ANP 0.05 mg x kg(‐1) x min(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low dose ANP
Number of subjects: 8
Study: 8956392

Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 24

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 24
Study: 1414321

Group type: EXPERIMENTAL
Intervention: SCMC-Lys (mucoregulatory drug)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 40
Study: 2865251

Group type: EXPERIMENTAL
Intervention: oral concentrate
Number of subjects: 159

Group type: COMPARATOR
Intervention: intramuscular medication
Number of subjects: 159
Study: 31660915

Group type: EXPERIMENTAL
Intervention: Integrated delivery of mass drug administration (MDA) for soil-transmitted helminths (STH) and mass dog rabies vaccination (MDRV)
Number of subjects: 24

Group type: COMPARATOR
Intervention: MDA only (Arm B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: MDRV only (Arm C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Integrated delivery (Arm A)
Number of subjects: 24
Study: 29672719

Group type: EXPERIMENTAL
Intervention: Hormonal contraceptive users (n=110)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Nonusers of hormonal contraceptives (n=66)
Number of subjects: 201
Study: 26815932

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Oral systemic antibiotics
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1255
Study: 23257663

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injection (IVRI) 0.5 mg/0.05 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 40
Study: 20303785

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 3223

Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN)
Number of subjects: 3223
Study: 21132065

Group type: EXPERIMENTAL
Intervention: High personal mastery (control component)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: High fatalism scores
Number of subjects: 73
Study: 16051446

Group type: EXPERIMENTAL
Intervention: Bromocriptine (maximum dose 2.5mg po tid)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bromocriptine and Placebo
Number of subjects: 70
Study: 12506163

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: CHOP‐B (cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: CHOP‐B
Number of subjects: 228
Study: 11002958

Group type: EXPERIMENTAL
Intervention: Teaching programme (early group)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (late group)
Number of subjects: 117
Study: 8809437

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (RA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (48 subjects aged 19 to 65 years)
Number of subjects: 30
Study: 1468291

Group type: EXPERIMENTAL
Intervention: CT‐102 APST
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 13
Study: 3898794

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30911301

Group type: EXPERIMENTAL
Intervention: Autologous platelet released growth factor (APRGF) injection (1-2 cc)
Number of subjects: 10
Study: 30232851

Group type: EXPERIMENTAL
Intervention: Medication plus fire-needle stimulation and cupping (Famciclovir 0.25 g three times a day, Mecobalamin 0.5 g three times a day, plus fire-needle stimulation and cupping once a day for 7 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication (Famciclovir 0.25 g three times a day, Mecobalamin 0.5 g three times a day)
Number of subjects: 60
Study: 27636931

Group type: EXPERIMENTAL
Intervention: Afobazole (30 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Diazepam (30 mg/day)
Number of subjects: 150
Study: 24835324

Group type: EXPERIMENTAL
Intervention: Routine stress myocardial perfusion scintigraphy (MPS)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Normal MPS findings
Number of subjects: 339
Study: 23088391

Group type: EXPERIMENTAL
Intervention: Hospital pay-for-performance demonstration project
Number of subjects: 420211

Group type: COMPARATOR
Intervention: Comparison hospitals (780 propensity-score-matched)
Number of subjects: 420211
Study: 20064680

Group type: EXPERIMENTAL
Intervention: 30 g of mixed nuts daily for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no nuts)
Number of subjects: 50
Study: 17938984

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Raloxifene (after open-label treatment)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo (after open-label treatment)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Raloxifene (at study end)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo (at study end)
Number of subjects: 329